Open Access
Review

Cerebrospinal fluid biomarkers of Alzheimer’s disease in healthy elderly

Catherine Randall1,Lisa Mosconi1,Mony de Leon1,Lidia Glodzik1,*
1
Center for Brain Health, 145 East 32nd Street, 5th floor. New York, NY 10016, USA
DOI: 10.2741/4170 Volume 18 Issue 3, pp.1150-1173
Published: 01 June 2013
(This article belongs to the Special Issue The polyhedral aspects of dementia)
*Corresponding Author(s):  
Lidia Glodzik
E-mail:  
Lidia.Glodzik@nyumc.org
Abstract

Numerous studies have shown that Alzheimer’s Disease (AD) pathology begins before the onset of clinical symptoms. Because therapies are likely to be more effective if they are implemented early in the disease progression, it is necessary to identify reliable biomarkers to detect AD pathology in the early stages of the disease, ideally in presymptomatic individuals. Recent research has identified three candidate cerebrospinal fluid (CSF) biomarkers that reflect AD pathology: amyloid beta, total tau protein (t-tau), and tau protein phosphorylated at ADspecific epitopes (p-tau). They are useful in supporting the AD diagnosis and have predictive value for AD when patients are in the stage of mild cognitive impairment (MCI). However, their predictive utility in cognitively healthy subjects is still being evaluated. We conducted a review of studies published between 1993 and 2011 and summarized their findings on the role of CSF biomarkers for AD in healthy elderly.

Key words

Alzheimer’s disease, Cerebrospinal fluid, Biomarkers, Imaging, Atrophy, ApoE, Tau, Amyloid beta, Phosphorylated tau, Normal populations, Review

Share and Cite
Catherine Randall, Lisa Mosconi, Mony de Leon, Lidia Glodzik. Cerebrospinal fluid biomarkers of Alzheimer’s disease in healthy elderly. Frontiers in Bioscience-Landmark. 2013. 18(3); 1150-1173.